Analysts at Maxim Group have initiated coverage of Momenta Pharmaceuticals, Inc. (MNTA) with a buy rating.
The firm set its price target on the stock at $24 a share, which is more than double its current market price.
Shares of MNTA are up 1% to $10.42 in the pre-market session, amid a 52-week trading range of $9.85 – $19.90.
Latest posts by Kevin Calderon (see all)
- AMD Epyc Processor Units – A Rival for Intel? - Jun 22, 2017
- Climate Change Study Had To Be Postponed Due To The Severe Ice Conditions - Jun 15, 2017
- Aldi Is Planning On Increasing Its Presence In The US Market - Jun 12, 2017